Stock listing
Lang & Schwarz:A2GS5D Dermapharm Holding SE Aktie
German listing (Lang & Schwarz) of Dermapharm Holding SE · home listing Xetra:DMP
Follow Dermapharm Holding SE into a list and get an email when it puts out news.
Home listing price · XETR:DMP
€32.75 EUR -1.30 (-3.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, XETR:DMP
- Day range
- €32.75 – €33.45 EURNov 20, 2026
- Volume
- 42,627 sharesNov 20, 2026
- Market cap
- €1.62B EURAt the close on Nov 20, 2026 · price × 49.54M shares outstanding
- 52-week range
- €32.75 – €51.90 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1.26M EURMedian day 22,921 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Xetra:DMP · Home | €32.75 EUR | -1.30 (-3.8%) | 42,627 | €32.95 | €33.45 | €32.75 | €34.05 | Close on Nov 20, 2026 |
| OTC:DMPHF | $38.84 USD | -8.85 (-18.6%) | 200 | $38.84 | $38.84 | $38.84 | $47.69 | Close on Nov 13, 2026 |
| Dusseldorf:DMP | €32.80 EUR | -0.50 (-1.5%) | — | €32.55 | €33.15 | €32.55 | €33.30 | Close on Nov 20, 2026 |
| Hamburg:DMP | €33.30 EUR | -0.60 (-1.8%) | 120 | €32.55 | €33.30 | €32.55 | €33.90 | Close on Nov 20, 2026 |
| Munich:DMP | €32.95 EUR | -1.40 (-4.1%) | — | €32.95 | €32.95 | €32.95 | €34.35 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · XETR:DMP · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €32.75 | -1.30 | -3.8% | €32.95 | €33.45 | €32.75 | 42,627 | |
| €34.05 | -0.95 | -2.7% | €35.35 | €35.35 | €33.90 | 34,739 | |
| €35.00 | -0.45 | -1.3% | €35.25 | €35.45 | €34.75 | 32,375 | |
| €35.45 | +0.20 | +0.6% | €35.20 | €35.70 | €34.80 | 26,549 | |
| €35.25 | +0.30 | +0.9% | €35.35 | €35.85 | €34.85 | 49,688 | |
| €34.95 | -3.65 | -9.5% | €37.90 | €38.70 | €34.95 | 116,463 | |
| €38.60 | +0.10 | +0.3% | €38.90 | €39.20 | €38.50 | 21,340 | |
| €38.50 | +0.15 | +0.4% | €38.60 | €38.60 | €37.95 | 28,426 | |
| €38.35 | +0.35 | +0.9% | €38.20 | €38.55 | €37.90 | 13,366 | |
| €38.00 | -0.50 | -1.3% | €38.10 | €38.55 | €37.45 | 23,591 | |
| €38.50 | -0.40 | -1.0% | €39.00 | €39.35 | €38.25 | 13,229 | |
| €38.90 | +0.45 | +1.2% | €38.55 | €39.05 | €38.30 | 8,350 | |
| €38.45 | -0.65 | -1.7% | €38.85 | €39.05 | €38.35 | 13,592 | |
| €39.10 | +0.55 | +1.4% | €38.50 | €39.15 | €38.50 | 8,213 | |
| €38.55 | 0.00 | 0.0% | €38.50 | €38.70 | €38.40 | 5,424 | |
| €38.55 | +0.35 | +0.9% | €38.20 | €38.55 | €38.15 | 17,671 | |
| €38.20 | -0.20 | -0.5% | €38.25 | €38.70 | €38.10 | 15,757 | |
| €38.40 | +0.55 | +1.5% | €38.70 | €38.70 | €37.80 | 11,217 | |
| €37.85 | -0.55 | -1.4% | €38.50 | €38.95 | €37.85 | 11,031 | |
| €38.40 | -0.30 | -0.8% | €38.70 | €38.75 | €38.20 | 18,424 | |
| €38.70 | -0.10 | -0.3% | €38.60 | €38.90 | €38.45 | 9,838 | |
| €38.80 | +0.55 | +1.4% | €38.00 | €39.05 | €38.00 | 14,649 | |
| €38.25 | +0.35 | +0.9% | €37.40 | €38.35 | €37.40 | 11,373 | |
| €37.90 | +0.05 | +0.1% | €37.55 | €38.25 | €37.55 | 34,732 | |
| €37.85 | -0.30 | -0.8% | €38.70 | €38.70 | €37.65 | 14,600 | |
| €38.15 | -0.40 | -1.0% | €38.35 | €38.85 | €38.15 | 27,513 | |
| €38.55 | +0.70 | +1.8% | €38.00 | €38.85 | €37.85 | 15,973 | |
| €37.85 | -0.45 | -1.2% | €38.30 | €38.50 | €37.85 | 10,213 | |
| €38.30 | -0.10 | -0.3% | €38.75 | €38.75 | €38.05 | 12,585 | |
| €38.40 | +0.25 | +0.7% | €38.15 | €38.90 | €38.15 | 11,821 | |
| €38.15 | -0.75 | -1.9% | €38.65 | €38.75 | €38.00 | 18,235 | |
| €38.90 | +0.80 | +2.1% | €37.75 | €39.10 | €37.75 | 30,849 | |
| €38.10 | +0.65 | +1.7% | €37.35 | €38.35 | €37.35 | 43,542 | |
| €37.45 | -0.05 | -0.1% | €37.40 | €38.05 | €37.35 | 17,100 | |
| €37.50 | -0.95 | -2.5% | €38.40 | €38.40 | €37.40 | 23,954 | |
| €38.45 | -0.75 | -1.9% | €38.90 | €38.95 | €38.25 | 14,727 | |
| €39.20 | +0.15 | +0.4% | €39.00 | €39.70 | €39.00 | 14,969 | |
| €39.05 | -0.30 | -0.8% | €39.35 | €39.60 | €39.05 | 12,557 | |
| €39.35 | +0.30 | +0.8% | €39.05 | €39.50 | €39.05 | 14,498 | |
| €39.05 | -0.25 | -0.6% | €39.10 | €39.40 | €38.95 | 15,019 | |
| €39.30 | +0.05 | +0.1% | €39.05 | €39.60 | €39.00 | 22,250 | |
| €39.25 | -0.50 | -1.3% | €39.85 | €39.85 | €39.20 | 18,478 | |
| €39.75 | +0.95 | +2.4% | €38.70 | €39.95 | €38.70 | 28,469 | |
| €38.80 | -0.10 | -0.3% | €39.20 | €39.20 | €38.60 | 26,550 | |
| €38.90 | -0.10 | -0.3% | €39.25 | €39.85 | €38.90 | 85,291 | |
| €39.00 | +0.45 | +1.2% | €38.30 | €39.15 | €38.30 | 14,413 | |
| €38.55 | +0.75 | +2.0% | €38.45 | €38.85 | €38.00 | 20,577 | |
| €37.80 | -0.10 | -0.3% | €38.00 | €38.00 | €37.45 | 50,921 | |
| €37.90 | +0.50 | +1.3% | €37.25 | €38.05 | €37.25 | 44,305 | |
| €37.40 | -0.90 | -2.3% | €38.30 | €38.30 | €37.35 | 43,615 | |
| €38.30 | -0.50 | -1.3% | €38.55 | €38.70 | €38.20 | 29,073 | |
| €38.80 | -0.15 | -0.4% | €38.15 | €39.20 | €38.15 | 28,704 | |
| €38.95 | +0.40 | +1.0% | €38.70 | €39.10 | €38.35 | 31,315 | |
| €38.55 | -1.05 | -2.7% | €39.55 | €39.55 | €38.20 | 34,423 | |
| €39.60 | +0.65 | +1.7% | €38.50 | €39.60 | €38.50 | 28,800 | |
| €38.95 | +0.65 | +1.7% | €38.30 | €39.35 | €38.30 | 40,395 | |
| €38.30 | -0.70 | -1.8% | €38.80 | €38.85 | €38.30 | 38,152 | |
| €39.00 | 0.00 | 0.0% | €40.15 | €40.15 | €38.95 | 11,839 | |
| €39.00 | -0.55 | -1.4% | €39.50 | €39.50 | €39.00 | 476,211 | |
| €39.55 | -0.55 | -1.4% | €39.95 | €40.30 | €39.40 | 28,808 | |
| €40.10 | +0.05 | +0.1% | €39.45 | €40.40 | €38.70 | 28,586 | |
| €40.05 | -1.95 | -4.6% | €41.00 | €41.55 | €40.05 | 36,571 | |
| €42.00 | +2.20 | +5.5% | €40.20 | €42.15 | €39.45 | 55,530 | |
| €39.80 | -0.35 | -0.9% | €39.95 | €40.15 | €39.60 | 22,063 | |
| €40.15 | +0.25 | +0.6% | €39.90 | €40.15 | €39.30 | 24,191 | |
| €39.90 | -0.40 | -1.0% | €40.80 | €40.80 | €39.65 | 25,977 |
- Ticker
- Lang & Schwarz:A2GS5D
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Aug 25, 2026
Dermapharm confirms profitable growth in H1 2026 and increases adjusted EBITDA
Latest earnings call · Aug 25, 2026
Dermapharm Holding (Xetra:DMP) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Dermapharm Hldg — Q3 2026 Earnings Presentation
Earnings · 24 slides
Latest news
Dermapharm confirms profitable growth in H1 2026 and increases adjusted EBITDA
Aug 25, 2026
Closed €42.00 (+5.5%) on Aug 25, 2026
Dermapharm Holding SE reports profitable growth in H1 2026 and confirms guidance
Aug 11, 2026
Closed €39.75 (-1.9%) on Aug 11, 2026
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Jun 26, 2026
Closed €47.60 (+2.3%) on Jun 26, 2026
Dermapharm Holding SE performs in line with projections in Q1 2026 and confirms guidance
May 13, 2026
Closed €46.90 (+1.3%) on May 13, 2026
Dermapharm Holding SE reports dip in revenue, rise in adjusted consolidated EBITDA and margin
Mar 31, 2026
Closed €42.30 (-3.6%) on Mar 31, 2026
Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Mar 26, 2026
Closed €42.40 (-4.7%) on Mar 27, 2026
Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares
Mar 10, 2026
Closed €41.40 (+8.5%) on Mar 10, 2026
Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves
Mar 10, 2026
Closed €41.40 (+8.5%) on Mar 10, 2026
Dermapharm Holding SE on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 8 in the last 12 months · 10 in all · newest Aug 25, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 25, 2026
- Decks
- 51 decks · latest Nov 12, 2026
Where Dermapharm Holding SE is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Xetra:DMP · Home listing | Xetra | Germany | EUR |
| Tradegate:DMP | Tradegate | Germany | EUR |
| gettex:DMP | gettex | Germany | EUR |
| Stuttgart:DMP | Stuttgart | Germany | EUR |
| LS Exchange:A2GS5D | LS Exchange | Germany | EUR |
| LSIN:0A5J | LSIN | United Kingdom | EUR |
| OTC:DMPHF | OTC | United States | USD |
| Frankfurt:DMP | Frankfurt | Germany | EUR |
| Hanover:DMP | Hanover | Germany | EUR |
| Lang & Schwarz:A2GS5D · This page | Lang & Schwarz | Germany | EUR |
| BX Swiss:DMP | BX Swiss | Switzerland | CHF |
| Dusseldorf:DMP | Dusseldorf | Germany | EUR |
| Hamburg:DMP | Hamburg | Germany | EUR |
| Munich:DMP | Munich | Germany | EUR |
| Aquis:DMPD | Aquis | United Kingdom | EUR |
| VIE:DMP | Vienna | Austria | EUR |
| Aquis:DMPD | Aquis | United Kingdom | EUR |
| Turquoise:DMPD | Turquoise | United Kingdom | EUR |
Valuation
P/E 12.4× against a median of 19.1×: 3rd lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- €2.62B EUR
- P/E
- 12.4×
- EV/sales
- 2.2×
- EV/EBITDA
- 6.9×
- Price/book
- 2.9×
- Gross margin
- 33.8%
- Operating margin
- 20.9%
- Net margin
- 11.1%
- Debt to equity
- 2.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dermapharm Holding SE · XETR:DMP | US$1.78B | US$2.88B | 12.4× | 2.2× | 6.9× | 2.9× | 11.1% | 2.0× | n/a |
| Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A · SSE:603707 | US$1.90B | US$1.52B | 29.8× | 2.5× | n/a | 1.8× | 10.4% | 0.0× | n/a |
| Shenzhen Kangtai Biological Products Co. Ltd. Class A · SZSE:300601 | US$1.80B | US$1.74B | 103× | 4.7× | n/a | 1.2× | 4.8% | 0.2× | n/a |
| Shilpa Medicare Limited · NSE:SHILPAMED | US$1.79B | US$1.85B | 50.0× | 9.3× | 33.5× | 6.0× | 18.1% | 0.2× | n/a |
| Shenyang Xingqi Pharmaceutical Co., Ltd. Class A · SZSE:300573 | US$1.76B | US$1.69B | 14.6× | 4.0× | n/a | 5.2× | 28.6% | 0.0× | n/a |
| Eton Pharmaceuticals, Inc. · NASDAQ:ETON | US$1.76B | US$1.71B | 35.2× | 12.1× | 38.7× | 20.2× | 35.4% | 0.1× | 0.57 |
| United Laboratories International Holdings Ltd. · HKEX:3933 | US$1.73B | US$863.1M | 5.5× | 0.4× | 2.0× | 0.7× | 15.8% | 0.3× | n/a |
| H. Lundbeck A/S Class A · OMXCOP:HLUN_A | US$1.71B | US$2.45B | 2.9× | 0.6× | 1.7× | 0.4× | 15.5% | 0.3× | n/a |
| Harbin Pharmaceutical Group Co., Ltd. Class A · SSE:600664 | US$1.70B | US$1.22B | 17.9× | 0.5× | n/a | 1.8× | 3.9% | 0.0× | n/a |
| Mayinglong Pharmaceutical Group Co., Ltd. Class A · SSE:600993 | US$1.70B | US$1.34B | 19.1× | 2.2× | n/a | 2.5× | 14.9% | 0.0× | n/a |
| Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE | US$1.68B | US$2.60B | n/a | 3.6× | n/a | n/a | −71.8% | n/a | 1.35 |
| Median of the others | US$1.74B | US$1.70B | 19.1× | 3.0× | 17.7× | 1.8× | 15.2% | 0.1× | 0.96 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 51.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- 2.53 · 1 analyst
- Revenue, year to Dec 2026
- 1.19B · 3 analysts
Team and board
| Officer | Role |
|---|---|
| Britta Hamberger | Investor Relations & Corporate Communications |
| Dermapharm Holding SE | ir.dermapharm.de |
Events
Calls
| Call | When | Status |
|---|---|---|
| Dermapharm Holding (Xetra:DMP) Q2 2026 Earnings Call | Tue, Aug 25, 2026 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +0.9% |
| Q2 2026 | Aug 25, 2026 · After close | −4.6% |
| Q1 2026 | May 13, 2026 · After close | +7.7% |
| Q4 2025 | Mar 30, 2026 · After close | −3.6% |
| Q3 2025 | Nov 13, 2025 · After close | +2.2% |
| Q2 2025 | Aug 26, 2025 · After close | +1.2% |
| Q1 2025 | May 15, 2025 · Before open | −8.7% |
| Q4 2024 | Mar 14, 2025 | +11.3% |
| Q3 2024 | Nov 14, 2024 · Before open | +8.6% |
| Q2 2024 | Aug 27, 2024 · Before open | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | +3.3% |
| Q4 2023 | Mar 28, 2024 · Before open | −4.5% |
| Q3 2023 | Nov 15, 2023 · Before open | +0.6% |
| Q2 2023 | Aug 16, 2023 · Before open | +12.8% |
| Q1 2023 | May 15, 2023 · Before open | +8.0% |
| Q4 2022 | Mar 28, 2023 · Before open | +0.6% |
| Q3 2022 | Nov 16, 2022 · Before open | +2.5% |
| Q2 2022 | Sep 7, 2022 · Before open | −3.3% |
| Q1 2022 | May 18, 2022 · Before open | −13.4% |
| Quarter to Sep 30, 2021 | Nov 16, 2021 | −6.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Dermapharm Hldg — Q3 2026 Earnings Presentation | Earnings | 24 slides | Nov 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 13, 2026 |
| FY2025 Earnings Presentation | Earnings | 24 slides | Mar 31, 2026 |
| Fact Sheet (2026) | Fact sheet | 2 slides | Mar 30, 2026 |
| Fact Sheet (December 2025) | Fact sheet | 2 slides | Dec 31, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 23 slides | Nov 13, 2025 |
| H1 2025 Earnings Presentation | Earnings | 23 slides | Aug 26, 2025 |
| Fact Sheet (June 2025) | Fact sheet | 2 slides | Jun 30, 2025 |
| Shareholder Meeting (June 2025) | Shareholder meeting | 15 slides | Jun 26, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 22 slides | May 15, 2025 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2024 Earnings Presentation | Earnings | 24 slides | Mar 28, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 23 slides | Nov 14, 2024 |
| Fact Sheet (November 2024) | Fact sheet | 2 slides | November 2024 |
| H1 2024 Earnings Presentation | Earnings | 22 slides | Aug 27, 2024 |
| Fact Sheet (June 2024) | Fact sheet | 2 slides | Jun 30, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 20 slides | May 15, 2024 |
| Fact Sheet (March 2024) | Fact sheet | 2 slides | March 2024 |
| Fact Sheet (March 2024) | Fact sheet | 2 slides | March 2024 |
| Fact Sheet (March 2024) | Fact sheet | 2 slides | March 2024 |
| Q3 2023 Earnings Presentation | Earnings | 21 slides | Nov 15, 2023 |
| Q3 2023 Earnings Presentation | Earnings | 17 slides | Nov 15, 2023 |
| H1 2023 Earnings Presentation | Earnings | 28 slides | Aug 29, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 19 slides | May 15, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 16 slides | May 15, 2023 |
| Investor Day (November 2022) | Investor day | 48 slides | Nov 22, 2022 |
| H1 2022 Earnings Presentation | Earnings | 18 slides | Sep 7, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 18 slides | May 18, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 14 slides | May 18, 2022 |
| FY2021 Earnings Presentation | Earnings | 21 slides | Apr 12, 2022 |
| Investor Day (2022) | Investor day | 29 slides | 2022 |
| Investor Day (2022) | Investor day | 15 slides | 2022 |
| Investor Day (2022) | Investor day | 35 slides | 2022 |
| Q3 2021 Earnings Presentation | Earnings | 17 slides | Nov 16, 2021 |
| H1 2021 Earnings Presentation | Earnings | 17 slides | Sep 7, 2021 |
| Shareholder Meeting (June 2021) | Shareholder meeting | 27 slides | Jun 23, 2021 |
| Q1 2021 Earnings Presentation | Earnings | 17 slides | May 18, 2021 |
| FY2020 Earnings Presentation | Earnings | 22 slides | Apr 13, 2021 |
| Q3 2020 Earnings Presentation | Earnings | 17 slides | Nov 16, 2020 |
| H1 2020 Earnings Presentation | Earnings | 17 slides | Sep 9, 2020 |
| Shareholder Meeting (June 2020) | Shareholder meeting | 20 slides | Jun 17, 2020 |
| Q1 2020 Earnings Presentation | Earnings | 17 slides | May 19, 2020 |
| FY2019 Earnings Presentation | Earnings | 22 slides | Apr 8, 2020 |
| Q3 2019 Earnings Presentation | Earnings | 14 slides | Nov 20, 2019 |
| H1 2019 Earnings Presentation | Earnings | 16 slides | Sep 12, 2019 |
| Shareholder Meeting (June 2019) | Shareholder meeting | 25 slides | Jun 4, 2019 |
| Q1 2019 Earnings Presentation | Earnings | 16 slides | May 21, 2019 |
| FY2018 Earnings Presentation | Earnings | 22 slides | Apr 17, 2019 |
| Q3 2018 Earnings Presentation | Earnings | 23 slides | Nov 20, 2018 |
| H1 2018 Earnings Presentation | Earnings | 22 slides | Sep 12, 2018 |
| Shareholder Meeting (June 2018) | Shareholder meeting | 34 slides | Jun 26, 2018 |
This page holds 50 of 51 decks. Open Decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.18B | 1.14B | 1.02B | 942.9M | 793.8M | 700.9M | 572.4M | 467.1M | 444.5M |
| Cost of revenue | 773.3M | 413.7M | 416.2M | 363.9M | 322.2M | 330.3M | 317.2M | 272.7M | 245.6M | 243.4M |
| Gross profit | 391.7M | 767.1M | 719.2M | 660.8M | 620.7M | 463.5M | 383.7M | 299.8M | 221.5M | 201.0M |
| Research and development | 11.2M | 11.5M | 10.6M | 13.2M | 14.2M | 12.7M | 11.2M | 6.96M | 6.64M | 4.82M |
| Selling, general and administrative | 13.2M | 13.6M | 20.2M | 16.1M | 13.1M | 14.7M | 12.7M | 9.83M | 6.93M | 3.25M |
| Operating income | 221.7M | 216.9M | 182.9M | 243.7M | 298.5M | 136.9M | 119.5M | 107.5M | 92.1M | 86.8M |
| Depreciation and amortization | 92.6M | 86.8M | 104.6M | 94.9M | 55.2M | 47.4M | 47.9M | 24.1M | 16.2M | 14.1M |
| EBITDA | 314.3M | 303.7M | 287.5M | 338.6M | 353.6M | 184.3M | 167.4M | 131.6M | 108.3M | 100.9M |
| Interest expense | 52.7M | 58.4M | 59.5M | 13.9M | 9.85M | 10.6M | 10.9M | 7.57M | 7.55M | 9.69M |
| Income before tax | 183.5M | 172.0M | 106.0M | 216.3M | 293.0M | 125.3M | 110.1M | 104.2M | 88.0M | 82.9M |
| Income tax | 52.2M | 60.3M | 45.5M | 83.7M | 84.1M | 39.4M | 32.3M | 29.0M | 10.3M | 5.87M |
| Net income | 132.4M | 113.8M | 62.4M | 134.2M | 209.6M | 85.8M | 77.2M | 75.3M | 77.7M | 16.8M |
| Earnings per share, basic | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 | 1.59 | 1.43 | 1.41 | 1.44 | 0.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 203.4M | 121.2M | 158.7M | 149.9M | 160.3M | 120.6M | 115.0M | 212.8M | 6.29M | 3.82M |
| Short-term investments | 735.0K | 511.0K | 818.0K | 11.4M | 11.7M | 1.04M | 1.06M | 1.10M | 400.0K | 30.0K |
| Receivables | 121.4M | 105.0M | 95.4M | 100.1M | 76.1M | 55.5M | 53.0M | 34.1M | 102.6M | 66.2M |
| Inventory | 328.7M | 339.9M | 320.8M | 251.8M | 240.5M | 203.3M | 172.2M | 115.6M | 81.1M | 84.6M |
| Current assets | 702.9M | 593.5M | 630.5M | 533.9M | 519.2M | 400.1M | 352.9M | 371.2M | 192.9M | 157.0M |
| Property, plant and equipment | 318.5M | 315.0M | 330.8M | 225.7M | 222.3M | 199.6M | 132.6M | 80.9M | 56.0M | 53.4M |
| Goodwill | 587.1M | 576.4M | 578.5M | 271.3M | 264.7M | 266.3M | 202.2M | 54.6M | 24.6M | 17.0M |
| Total assets | 2.20B | 2.08B | 2.16B | 1.41B | 1.41B | 1.22B | 1.04B | 704.6M | 415.3M | 311.7M |
| Accounts payable | 96.3M | 94.8M | 86.6M | 56.1M | 52.1M | 50.4M | 35.4M | 28.2M | 23.4M | 24.5M |
| Current liabilities | 342.9M | 326.9M | 394.5M | 217.8M | 155.6M | 132.9M | 102.4M | 146.4M | 80.6M | 115.4M |
| Long-term debt | 904.1M | 877.3M | 950.7M | 501.8M | 565.7M | 570.5M | 533.6M | 232.6M | 222.3M | 96.8M |
| Total debt | 1.05B | 979.6M | 1.08B | 516.4M | 580.3M | 606.8M | 554.6M | 304.3M | 254.7M | 162.8M |
| Total liabilities | 1.50B | 1.47B | 1.62B | 880.3M | 907.1M | 899.8M | 760.4M | 448.5M | 341.6M | 250.9M |
| Shareholders' equity | 694.4M | 604.4M | 539.2M | 531.6M | 497.3M | 322.0M | 278.6M | 252.4M | 73.7M | 56.9M |
| Shares outstanding | 53.8M | 53.8M | 53.8M | 53.8M | 53.8M | 53.8M | 53.8M | 53.4M | 53.8M | 53.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 181.5M | 201.4M | 219.4M | 288.5M | 250.4M | 131.1M | 100.6M | 159.1M | 86.7M | 76.8M |
| Capital spending | -42.1M | -38.2M | -41.5M | -39.0M | -61.2M | -40.8M | -46.4M | -26.0M | -74.7M | -17.8M |
| Free cash flow | 139.4M | 163.1M | 177.9M | 249.5M | 189.2M | 90.3M | 54.2M | 133.2M | 12.0M | 59.0M |
| Cash from investing | -110.0M | -29.6M | -415.4M | -99.0M | -129.3M | -105.9M | -382.2M | -110.0M | -84.9M | -12.3M |
| Cash from financing | 13.3M | -209.2M | 204.5M | -199.8M | -81.0M | -14.1M | 184.0M | 164.4M | -7.98M | -55.9M |
| Dividends paid | -48.5M | -47.4M | -56.5M | -116.8M | -47.4M | -43.1M | -41.5M | -41.5M | -41.5M | -41.5M |
| Share buybacks | 0 | 107.5M | 120.0K | 120.0K | ||||||
| Change in cash | 82.1M | -37.4M | 7.70M | -10.4M | 41.1M | 11.3M | -97.4M | 213.6M | -6.15M | 8.59M |
Cap table
Built by 6ix from Dermapharm Holding SE’s releases
- Common shares
- 49,540,810
- Fully diluted
- 49,540,810
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 49,540,810 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 49,540,810 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Britta Hamberger | Investor Relations & Corporate Communications · Since at least Aug 25, 2026 |
| Dermapharm Holding SE | ir.dermapharm.de · Since at least Aug 25, 2026 |
Log in to ask 6ix AI your own questions about Dermapharm Holding SE.